Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]